Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06210685

The ACES Study for Aseptic Pleural Effusion

The study will enroll recurrent aseptic pleural effusion patients who are designated by their physician as needing treatment to control the fluid. Baseline assessment will include a history and physical, chest imaging and quality of life questionnaires.

After ACES implantation, patients will remain under hospital care for general observation as per standard-of-care before being discharged home with access to electronic diaries for tracking pain and dyspnea.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Memorial Healthcare System, Hollywood, Florida, United States

Loading trial locations.

About this study

Pleural Dynamics is the first company to provide a fully implantable automatic effusion shunt that is powered by normal breathing and is designed for continuous symptom relief, and does not require an extended hospital stay, a catheter external to the chest, or expensive drainage canisters."

The current standard of care, pleurodesis, is often painful, requires an extended hospital stay, and is often unsuccessful requiring additional procedures to manage the effusion1. While an alternate approach-indwelling pleural catheters-exists, it requires that the patient have a portion of the catheter to be external to the chest and requires frequent drainage into proprietary external canisters to relieve symptoms. Pleural Dynamics' patented ACES™ System addresses these shortcomings with its' one-piece, fully implanted system that can be placed during a short hospital stay. This technology is designed to use normal breathing motion to automatically pump pleural effusion fluid out of the chest to the abdomen for reabsorption by the body eliminating the need for an external catheter and frequent drainage, providing ongoing symptom relief.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Recurrent pleural effusion after thoracentesis for which the physician has determined that a catheter implantation is indicated.
  • Symptoms of PE such as shortness of breath, cough, or chest fullness/chest discomfort based on patient report to physician.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.
  • Patient is willing and able to meet all study requirements, including follow-up visits and receiving study related telephone calls.

Exclusion criteria

  • Recurrent pleural effusion after thoracentesis for which the physician has determined that a catheter implantation is indicated.
  • Symptoms of PE such as shortness of breath, cough, or chest fullness/chest discomfort based on patient report to physician.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.
  • Patient is willing and able to meet all study requirements, including follow-up visits and receiving study related telephone calls.

Treatment and study plan

Automatic Continuous Effusion Shunt implantation

Device

The catheter pump chamber is placed with part of the chamber between adjacent ribs and part of the chamber under the skin and external to the ribs. The pump chamber is used to transfer pleural fluid into the peritoneal cavity.

Other names: ACES Catheter

Primary outcomes

  1. Primary Efficacy Endpoint

    Time frame: 30 days

    Percentage change in pleural effusion volume via chest CT from baseline

Secondary outcomes

  1. Adverse Events

    Time frame: 30 and 60 days

    Rate of Adverse Events (serious and non-serious) including hospitalizations/visits

  2. Pleurodesis

    Time frame: 30 and 60 days

    Rate of Pleurodesis

  3. VAS Breathlessness Score

    Time frame: 30 and 60 days

    Change in VAS Breathlessness Score

Sponsors and collaborators

Lead sponsor

Pleural Dynamics, Inc.

Industry

Collaborators

  • Medical Metrics Diagnostics, Inc

Registry information

Official study title

A Post-Market Study Evaluating Fluid Shunting Using the Automatic Continuous Effusion Management System (ACES™) in Patients With Symptomatic Aseptic Pleural Effusion

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jan 18, 2024
Registry last updated
Aug 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.